Ascletis Pharma, Inc. (HK:1672) has released an update.
Ascletis Pharma Inc. has announced its plan to buy back shares worth up to HK$200 million under the Repurchase Mandate, aiming to enhance shareholder value and reflect confidence in the company’s long-term prospects. The board believes the current share price does not mirror the inherent value of the firm, which is in solid financial health. Share repurchases are subject to market conditions and will be conducted in accordance with the relevant Hong Kong regulations, without negatively impacting the company’s capital position.
For further insights into HK:1672 stock, check out TipRanks’ Stock Analysis page.
